MedPath

Clinical Trial News

Datopotamab Deruxtecan Shows Promise in Advanced Gynecologic Cancers

  • Datopotamab deruxtecan (Dato-DXd) demonstrates encouraging antitumor activity in patients with advanced ovarian cancer post-platinum chemotherapy.
  • In endometrial cancer, Dato-DXd showed a confirmed objective response rate of 27.5% with a median duration of response of 16.4 months.
  • The TROPION-PanTumor03 study indicates Dato-DXd has a manageable safety profile, with mostly low-grade stomatitis and nausea reported.
  • These findings suggest Dato-DXd could be a potential treatment option for patients with limited alternatives after platinum-based therapies.

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211RecruitingPhase 2
AstraZeneca
Posted 9/6/2022

HIV Prevention Breakthroughs Face Access Barriers in Africa

  • Lenacapavir, a twice-yearly injectable drug, showed 100% success in preventing HIV in young African women, but Gilead has not provided a timeline for affordable access.
  • Cabotegravir, another highly effective HIV prevention drug, remains largely unavailable in Africa despite successful trials there from 2017-2020.
  • Experts advocate for a new mandate requiring licensing, manufacturing, and distribution plans prior to conducting drug trials in low- and middle-income countries.
  • High HIV infection rates in Africa expedite and reduce the cost of drug trials, raising ethical concerns about access to the resulting therapies.

Kaida BioPharma Advances Novel Therapies for Gynecological Cancers, Launches Social Media Channels

  • Kaida BioPharma is focusing on developing innovative drugs for treatment-resistant gynecological cancers, addressing a critical unmet need.
  • The lead program, KAD101, is a novel biologic targeting the prolactin receptor, currently being developed for ovarian cancer with Phase 1 trials in 2025.
  • KAD101 has shown encouraging results in early clinical studies, demonstrating tumor reduction and a favorable safety profile as a daily injectable.
  • Kaida BioPharma has launched corporate social media channels to connect with investors, patients, and industry partners, enhancing its visibility.

Sharing Clinical Trial Results Boosts Engagement and Offers Secondary Health Benefits

  • Providing clinical trial participants with their medical test results significantly enhances their engagement and willingness to participate in future research efforts.
  • A study within the RECOVER initiative found that two-thirds of participants valued receiving test results, leading to informed discussions with their primary care providers.
  • Nearly three-quarters of participants shared results with their doctors, sometimes leading to new treatments, highlighting the potential for improved healthcare outcomes.
  • Researchers emphasize the need to proactively plan and budget for returning test results to participants, ensuring a stress-free and meaningful experience.

FDA Grants Fast Track Designation to Glycomine's GLM101 for PMM2-CDG Treatment

  • The FDA has granted Fast Track designation to Glycomine's GLM101, a mannose-1-phosphate replacement therapy, for treating phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
  • GLM101 is currently in a Phase 2 clinical study involving adult and adolescent patients, with plans to expand enrollment to pediatric patients aged two years and older.
  • Initial data from the Phase 2 study suggests promising clinical benefits with GLM101, showing good tolerability and only mild to moderate adverse events reported to date.
  • Fast Track designation will allow for more frequent interactions with the FDA, potentially accelerating the approval process for GLM101, addressing a significant unmet need.

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

NCT05549219Active, Not RecruitingPhase 2
Glycomine, Inc.
Posted 11/29/2022

Azitra's ATR-04 Receives FDA Fast Track Designation for EGFRi-Associated Skin Rash

  • Azitra's ATR-04, a topical therapy for moderate to severe skin rash induced by EGFR inhibitors, has received FDA Fast Track designation.
  • The Fast Track program aims to expedite the development and review of drugs addressing serious conditions with unmet medical needs, potentially accelerating ATR-04's approval.
  • ATR-04 is a live biotherapeutic product with a modified Staphylococcus epidermidis strain, designed to enhance safety and address skin immunity suppression.
  • Azitra plans to initiate a Phase I/II clinical trial by the end of 2024 to evaluate ATR-04's efficacy and safety in treating EGFR inhibitor-induced dermal toxicity.

FDA Lifts Partial Clinical Hold on Vigil Neuroscience's VG-3927 Phase I Trial, Expands to Alzheimer's Patients

  • The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase I trial of VG-3927, a treatment for neurodegenerative diseases, following a complete response from the company.
  • Interim data from the trial indicated VG-3927's safety, tolerability, and potential for once-daily dosing, alongside a sustained decline in soluble TREM2 levels in cerebrospinal fluid.
  • The Phase I trial has expanded to include Alzheimer's disease patients, including those with TREM2 or other disease-related genetic variations, to assess biomarker response.
  • Vigil Neuroscience plans to release complete Phase I data, including results from the Alzheimer's patient cohort, in the first quarter of next year.

Medtronic's Adaptive DBS Shows Promise in Parkinson's Disease Trial

  • Medtronic's ADAPT-PD trial evaluates adaptive deep brain stimulation (aDBS) using the Percept PC neurostimulator for Parkinson's disease, showing potential for personalized therapy.
  • Preliminary data indicates that aDBS can deliver targeted stimulation based on a patient’s brain state, potentially improving symptom control and reducing side effects compared to continuous DBS (cDBS).
  • The study, involving 68 participants, assesses aDBS efficacy in 'at-home' settings, focusing on increasing 'On' time without troublesome dyskinesias, a key measure of treatment success.
  • GlobalData analysis projects the neuromodulation device market to reach over $8.9 billion by 2027, with the DBS segment constituting $1.9 billion by 2030, highlighting significant growth potential.

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

NCT04547712Active, Not RecruitingNot Applicable
MedtronicNeuro
Posted 12/14/2020

Insilico Medicine's AI-Designed Drug Shows Promise in Phase IIa IPF Trial

  • Insilico Medicine's ISM001-055 met its primary safety endpoint and secondary efficacy endpoints in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF).
  • The AI-designed drug demonstrated a dose-dependent improvement in forced vital capacity (FVC), a key measure of lung function, in IPF patients.
  • The company plans to engage with regulatory authorities to design a Phase IIb study, exploring extended treatment durations and larger patient cohorts.
  • ISM001-055 targets TNIK, offering a novel approach to treating IPF by addressing both fibrosis and inflammation, potentially modifying the disease.

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT05938920Active, Not RecruitingPhase 2
InSilico Medicine Hong Kong Limited
Posted 6/19/2023

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983RecruitingPhase 2
InSilico Medicine Hong Kong Limited
Posted 2/8/2024

A4 Study Data Released to Accelerate Alzheimer's Research

  • The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study data is now available for download, promoting open science in dementia research.
  • Despite solanezumab not meeting its primary endpoints, the A4 study's data sharing has already generated approximately 60 peer-reviewed research articles.
  • Researchers can access clinical data, biosamples, and neuroimaging from nearly 1,200 participants to explore disease biology and potential treatments.
  • The A4 study's impact and data will be discussed at the 2024 NIH Alzheimer’s Research Summit, fostering further insights into Alzheimer's.

Trending News

1

Glenmark Launches Tevimbra, First Immuno-Oncology Drug in India for Lung and Esophageal Cancer Treatment

3 days ago
2

Percheron Therapeutics Acquires Phase II-Ready Anti-VISTA Cancer Immunotherapy HMBD-002 in $290M Deal

a day ago
3

Revolution Medicines Secures $2 Billion Funding Deal with Royalty Pharma for RAS Cancer Drug Development

3 days ago
4

Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results

2 days ago
5

NHS Delivers First Brain-Infused Gene Therapy for Rare AADC Deficiency, Showing Promising Results in Three-Year-Old Patient

2 days ago
6

Galderma Launches Phase II Trials of Nemolizumab for Systemic Sclerosis and Chronic Pruritus of Unknown Origin

2 days ago
7

OutSee Secures £1.8M Seed Funding to Advance AI-Powered Genomics Platform for Drug Discovery

3 days ago
8

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

a day ago
9

Valorum Biologics Secures Exclusive Rights to Commercialize Formycon's Eylea Biosimilar in North America

2 days ago
10

Stuart Therapeutics Reports Mixed Phase III Results for ST-100 Dry Eye Treatment

3 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy